30 March 2023 - - US-based biomanufacturing company National Resilience, Inc has signed a finance agreement for USD 410m in long-term loan financing from the US Department of Defense, working with the US International Development Finance Corp, the company said.

The loan financing will support Resilience's mission to establish significant domestic, end-to-end biomanufacturing capacity and capabilities for biologics (antibodies, proteins, multi-specifics), vaccines, and nucleic acids (including mRNA).

This expanded capacity, together with existing technology and capabilities across Resilience's biomanufacturing network, will help secure the nation's supply chain for vaccines and critical medicines, bolster pandemic preparedness and response, and help address a critical advanced manufacturing infrastructure shortage revealed by the COVID-19 pandemic.

Part of the financing will support the implementation of innovative manufacturing platforms and technologies that aim to reduce cost, strengthen the domestic supply chain, and increase the speed of vaccine supply.

The long-term financing also strengthens Resilience's ability to deliver the highest quality products to patients and to the 50-plus commercial customers that utilize its nearly two m square feet of end-to-end drug development capacity and solutions that span process and analytical development and GMP biomanufacturing across multiple therapeutic modalities.

With this support, Resilience will be able to manufacture a bn doses of vaccines within its manufacturing network in the United States and will continue to partner with biotech and biopharma innovators across the drug development life cycle.

Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell therapy, and gene therapy modalities).

Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of TODAY and tomorrow can be made quickly, safely, and at scale.

By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients' lives and protect biopharmaceutical supply chains against future disruptions.